Dr. Cameron Durrant, Chairman and CEO, Humanigen explains the condition called cytokine storm and how their research into GMCSF, the master switch of the cytokine storm, has led to the development of the drug lenzilumab, LENZ, that neutralizes GMCSF. Adding LENZ to Remdesivir has shown promising results in early clinical trials and Humanigen recently announced they have signed an agreement with the National Institutes of Health to test LENZ in a larger trial in the search for a therapeutic for COVID-19.
@humanigen #cytokinestorm #COVID19 #LENZ #Remdesivir #NIH
Humanigen.com
Download the transcript here
Empowered Patient Podcast